Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study - Wikidata - wikimedia - TriplyDB

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

http://www.wikidata.org/entity/Q33880042

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Emerging therapeutic agents for lung cancer Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment Checkpoint inhibitors in lung cancer: latest developments and clinical potential Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab Current state of immunotherapy for non-small cell lung cancer.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Combination immunotherapy: a road map.Checkpoint Blockade in Lung Cancer and Mesothelioma.PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells.Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.The evolutionary nature of the cancer immunotherapy revolution.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.MEDI 4736 (durvalumab) in non-small cell lung cancer.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics The role of neoantigens in response to immune checkpoint blockade.Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.Recent developments in the use of immunotherapy in non-small cell lung cancer.Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Chemotherapy remains an essential element of personalized care for persons with lung cancers.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

P2860

Q26738359-649CA225-C978-4FCC-8C5E-AF7A75DED34C Q26741101-13AC83D6-E6DF-4144-9B59-D63160EAD69D Q26745516-3A4B1765-C346-4A45-B773-E15E567C8A50 Q28070165-1C0C0B55-BF9C-43B0-8AB1-B8A058E7E544 Q28076294-E7DF0903-DBD2-415C-9691-E8AF9DC12364 Q28076467-086685F5-0896-4AC3-90F7-C6F0D7250BB5 Q30274619-A9088BA1-9DAF-447C-9265-718946F50C8A Q33645595-412BC516-F1B7-4313-B3DD-C32B3DB3FA61 Q33876861-3269DD32-2F02-4DC2-889D-A25699A19E88 Q33884361-FE12029A-2C94-44A3-AE14-5F280F9867C6 Q33890538-F286B4CE-CAB3-447F-B6BB-788B902C793C Q33913077-87AD8C79-760B-4DAD-9791-31EBD08ED517 Q34545316-3251BD9F-23D5-431E-BF8D-0271613D0005 Q34552128-C6EA605E-E8F1-4974-8859-2B2901F0D0F6 Q36295004-7D3BCD3A-C2BD-41E6-8D34-A3CE19B792FE Q36363579-76DF3E2A-C6C6-4EBB-9E66-927C8E9B1B4C Q37584395-BCA9F7D4-8849-4BDE-8A48-3117BDA4AFDC Q37702430-B3074205-4B8D-4712-BF29-747381B22E17 Q37708795-B4816269-3C25-463A-8191-7D1C7D9CACEB Q37739214-BC53E795-D398-4498-988D-27A3EAE81790 Q38375220-014021A2-80A0-498C-B822-69DF89AB3EB3 Q38629823-38E0FE0B-70C6-48C2-89B3-5F2D5F5FBA88 Q38636430-AF003E9D-E216-4574-94C9-B1E6A2C0D027 Q38638860-4D86EADE-CEE7-4F9F-8AEA-1C53B4509AE8 Q38640845-D38A8DD3-5865-466B-AA36-BBB373066C5A Q38658050-457CC807-99F2-4E7B-9F4C-270D277E64DD Q38687631-2C1BED3E-FCA1-4A5A-BDB4-FDE83AB3C552 Q38720801-9A1AC727-106D-421A-8392-261979D1B6E5 Q38748974-D081BCD6-3B22-4EA9-8CDF-185F22C82F7E Q38798968-7E22E173-DBEB-486B-99B1-404DC1878E11 Q38804812-28243846-A39F-452F-844B-235C46FED345 Q38807704-1F9DA155-1F6B-4FE6-A4AD-664215C1E6DE Q38819349-3619A576-7D4B-401E-AEEC-88B504E0B7D8 Q38826419-954AA8D7-09B0-4DBD-AD0F-E1E20B7D32DA Q38830398-9218D7CB-280B-439F-B30B-148C200A1CCF Q38832640-835B7761-99B2-4CA4-B33D-15667872A723 Q38838014-8729E504-958D-4A29-954D-04CF9C2C76EE Q38870763-C1F84E7C-E548-4929-939B-5384DE1D21D0 Q38899873-1D7B9A4C-C76F-402E-B06D-8D42DBCFDE31 Q38916160-ECF35A56-8512-4D7C-8732-1CB83783208E

P2860

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

http://www.wikidata.org/entity/Q33880042

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Safety and antitumour activity ...... a multicentre, phase 1b study

@ast

Safety and antitumour activity ...... a multicentre, phase 1b study

@en

type

label

Safety and antitumour activity ...... a multicentre, phase 1b study

@ast

Safety and antitumour activity ...... a multicentre, phase 1b study

@en

prefLabel

Safety and antitumour activity ...... a multicentre, phase 1b study

@ast

Safety and antitumour activity ...... a multicentre, phase 1b study

@en

P1433

Q33880042-D5210B43-0384-4A88-8A6F-0C8D53535BCD

P1476

Q33880042-F342C9EF-0447-44D6-9D94-5092D4E01D15

P2093

Q33880042-1539D26E-1122-414B-9691-0334E63748DE

Q33880042-799725B6-23D0-4D87-8F33-A34E5C7C0834

Q33880042-7C573B08-4324-49B9-8E98-CD5A35325071

Q33880042-85F3A34E-3F60-4ADA-8850-4E0DE053A9A6

Q33880042-99F77538-2F44-4507-AEA2-E692F9561D62

Q33880042-C82627A3-0C1F-40D1-BC79-78074481C14C

Q33880042-D01DEEA7-D64E-4B81-8409-0C58A2BE8504

Q33880042-DD978EC3-7DC7-410D-BC11-132BF68622FB

Q33880042-DDC09D22-C788-4E1C-85C5-0E78EE420B35

Q33880042-DEE694D7-F4B8-471B-B733-5AA2CFCBA671

P2860

Q33880042-2FD25618-EA2A-4B03-AEB9-4CC198152563

Q33880042-55082033-C526-4365-99D7-9754BB3FA523

Q33880042-6F590321-26F9-4DE8-AA29-3F6B65796C37

Q33880042-80F4275F-5608-4698-8ABD-A77EB5AF93AB

Q33880042-873F42D8-EA87-416C-9B83-A9E8C01625E7

Q33880042-8C7585E7-7B68-4486-9BB3-DB39779562F5

Q33880042-94C94CA4-D0A3-4C0E-BFA1-F59548B24C0F

Q33880042-B35BAE74-816C-4B6C-BC0A-D8875A139C48

Q33880042-C71278C4-FD22-4423-8CA4-4CEE1BD2C770

Q33880042-D4AB59D7-7CED-447C-8D63-7B7FCF718193

P304

Q33880042-88974BF5-54B1-48F4-8F25-E1449BE14320

P31

Q33880042-582325F2-5AAC-45FD-B226-14D621037CFF

P356

Q33880042-B1AD4497-E3CC-45C6-B48B-C0419A36683C

P433

Q33880042-C7231306-E8FA-4F7B-815F-C2799D16E018

P478

Q33880042-4BBD3274-1F64-491F-A50D-047DA9DCD075

P577

Q33880042-8056BE6D-8B88-4349-A22D-03A8202DF4AB

P698

Q33880042-3E088518-B4D1-4A11-96D9-4B04B13DD53B

P921

Q33880042-134652F0-CC5D-43F0-9EFA-82ED171B5922

P932

Q33880042-A5D53030-0FFC-450D-BF07-19C756B275D2

P356

S1470-2045(15)00544-6

P1433

The Lancet Oncology

P1476

Safety and antitumour activity ...... a multicentre, phase 1b study

@en

P2093

Ani Balmanoukian

http://www.w3.org/2001/XMLSchema#string

Ashok Gupta

http://www.w3.org/2001/XMLSchema#string

Jamie E Chaft

http://www.w3.org/2001/XMLSchema#string

Joyson J Karakunnel

http://www.w3.org/2001/XMLSchema#string

Keith Steele

http://www.w3.org/2001/XMLSchema#string

Naiyer A Rizvi

http://www.w3.org/2001/XMLSchema#string

Rachel E Sanborn

http://www.w3.org/2001/XMLSchema#string

Rajesh Narwal

http://www.w3.org/2001/XMLSchema#string

Sarah B Goldberg

http://www.w3.org/2001/XMLSchema#string

Scott Antonia

http://www.w3.org/2001/XMLSchema#string

P2860

Immuno-oncology combinations: a review of clinical experience and future prospects

Innate and adaptive immune cells in the tumor microenvironment

Nivolumab plus ipilimumab in advanced melanoma.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.

Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis

Tremelimumab: a review of development to date in solid tumors.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

P304

299-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(15)00544-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26858122

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5500167

http://www.w3.org/2001/XMLSchema#string